Evolution of targeted therapies in cancer: opportunities and challenges in the clinic

Area of Science:

• Oncology
• Pharmacology
• Biomarker Discovery

Background:

• Targeted therapies represent a significant advancement in cancer treatment, offering improved patient outcomes and reduced toxicity.
• Precision medicines, including novel molecular entities, have recently gained approval by targeting specific signaling proteins and immune pathways.
• These therapies necessitate precise patient selection and the identification of response biomarkers.

Purpose of the Study:

• To review the evolution of targeted therapies in oncology.
• To discuss the challenges associated with translating targeted therapy concepts into clinical practice.
• To highlight the importance of biomarkers in the era of precision medicine.

Main Methods:

• Literature review of recent advancements in targeted cancer therapies.
• Analysis of clinical development and approval of new molecular entities.
• Discussion of biomarker discovery and patient selection strategies.

Main Results:

• Targeted therapies have demonstrably improved patient survival and treatment efficacy.
• Recent approvals include novel agents targeting key cancer signaling and immune pathways.
• Biomarker discovery is essential for identifying patients who will benefit most from targeted treatments.

Conclusions:

• Targeted therapies have revolutionized cancer care, enhancing outcomes and minimizing side effects.
• The successful clinical translation of targeted therapies hinges on robust biomarker strategies and patient stratification.
• Continued research into targeted agents and predictive biomarkers is vital for advancing cancer treatment.